# Compare Ipamorelin, NAD+, Thymosin Alpha-1, and Tirzepatide — Peptide Med Group

> A side-by-side comparison of four Research Peptide Fundamentals compounds — ipamorelin, NAD+, thymosin alpha-1, and tirzepatide — by mechanism, trial depth, most notable finding, regulatory status, and key caution.

Ipamorelin, NAD+, thymosin alpha-1, and tirzepatide, compared on trial depth, most notable finding, and regulatory status — not on marketing claims.

## Start here

This page lines up [ipamorelin](/ipamorelin), [NAD+](/nad), [thymosin alpha-1](/thymosin-alpha-1), and [tirzepatide](/tirzepatide) side by side on one question: how much clinical-trial evidence exists for each, and what did it find. That's the organizing frame for this whole site.

The short answer: tirzepatide has the most and the strongest trial data, by a wide margin. Thymosin alpha-1 has run a real Phase 3 trial — and it came back null. NAD+ has solid human trials on blood levels and biomarkers but no dedicated outcome trial of its own. Ipamorelin has one small human trial, and it didn't work.

None of this is medical advice, and no dose mentioned in any cited study applies to a person reading this page.

## The comparison matrix

| Dimension | Ipamorelin | NAD+ | Thymosin Alpha-1 | Tirzepatide |
| --- | --- | --- | --- | --- |
| Mechanism class | Selective ghrelin-receptor (GHS-R1a) agonist | Redox coenzyme / cellular metabolite | Thymic immunomodulatory peptide (TLR2/TLR9) | Dual GIP/GLP-1 receptor agonist |
| Deepest human trial | Phase 2 RCT, n=114, missed primary endpoint [3] | Multiple RCTs on precursors, n in the hundreds [7][10] | Phase 3 RCT, n=1,106, sepsis, null result [11] | Multiple Phase 3 RCTs, n=751-2,539, FDA-approved [16][19] |
| Most notable finding | No significant benefit vs placebo in postoperative recovery [3] | Dose-dependent blood NAD+ increases across trials [7][10] | No 28-day mortality benefit in sepsis, despite an earlier smaller signal [11][15] | -20.2% body weight vs -13.7% for semaglutide, head-to-head, 72 weeks [16] |
| Regulatory status | Not approved anywhere; research chemical | Sold as supplement; injectable form compounded, not FDA-approved | Approved (thymalfasin) in 35+ countries; not FDA-approved in the US [12] | FDA-approved (T2D, weight management, sleep apnea) |
| Key caution | No long-term human safety data; class-level cardiac signal in a related compound [2] | Compounded injectable form recalled for contamination risk | US non-approval; unregulated research/compounded material [12] | Boxed thyroid warning; documented gallbladder/biliary signal [17][18] |

## Trial depth

Trial depth is the whole point of this comparison, and it separates the four compounds sharply. Tirzepatide has multiple completed Phase 3 randomized trials, each with over 700 participants, plus years of post-approval pharmacovigilance [16][19][20]. Thymosin alpha-1 has actually run a Phase 3 trial too — 1,106 patients, double-blind, multicenter — a real achievement for a compound this age, even though the result was negative [11]. NAD+'s trial base skips past the basic question of whether it raises blood levels safely — that's been answered cleanly, more than once [7][10] — but stops short of a hard clinical-outcome trial. Ipamorelin's entire controlled human record is a single 114-patient trial that missed its endpoint [3]. Everything else claimed about ipamorelin comes from animals or from unmonitored human use.

## Most notable finding

Each compound's headline finding tells you something different about where it stands. Tirzepatide's is a win: a statistically significant, head-to-head victory over its nearest single-receptor competitor [16]. NAD+'s is a mechanism confirmation: precursor dosing reliably raises blood NAD+, in a clean dose-response pattern, across separate trials [7][10]. Thymosin alpha-1's is a null result in the best-designed trial it's ever had — informative precisely because the trial was large and rigorous enough to trust the negative [11]. Ipamorelin's is also a null result, but from a much smaller, older, single trial — a thinner basis for confidence either way [3].

## Regulatory status

Only tirzepatide is FDA-approved as a drug in the United States — for type 2 diabetes, chronic weight management, and sleep apnea. Thymosin alpha-1 (thymalfasin) clears a similar bar, just not here: it's an approved drug in more than 35 other countries, with no US marketing approval [12]. NAD+ occupies a different lane entirely — sold as a dietary supplement, with an injectable, compounded form used in wellness clinics that carries none of a drug's regulatory oversight. Ipamorelin has never cleared approval anywhere; it remains a research chemical, sold outside any pharmaceutical quality-assurance chain.

## Key caution

Tirzepatide's defining caution is a documented one: a boxed thyroid warning from rodent data, and a real, pooled-trial signal for gallbladder and biliary disease [17][18]. Thymosin alpha-1's is really a reminder — its largest trial found no benefit, which should temper any claim built on smaller, earlier studies [11]. NAD+'s sharpest caution is about delivery, not the molecule: compounded injectable NAD+ has been the subject of an FDA Class I recall for bacterial contamination. Ipamorelin's caution is an absence — there is no long-term human safety data at all, and the closest thing to a cardiac signal comes from a related compound, not ipamorelin itself [2].

---

This is a citation ledger, not a clinic — we report what the trials found and stop there.